

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 July 2003 (10.07.2003)

PCT

(10) International Publication Number
WO 03/055998 A2

- (51) International Patent Classification⁷: **C12N 9/84**
- (21) International Application Number: **PCT/EP02/14610**
- (22) International Filing Date:
18 December 2002 (18.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1019667 27 December 2001 (27.12.2001) NL
- (71) Applicant (*for all designated States except US*): **DSM N.V.**
[NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ALKEMA, Wynand, Bernlef, Liudger** [NL/NL]; Getij 18, NL-9732 MN Grinigen (NL). **MOODY, Harold, Monro** [NL/NL]; Hoogzwanenstraat 148, NL-6211 BZ Maastricht (NL). **LAAN VAN DER, Jan, Metske** [NL/NL]; Leursebaan 364, NL-4839 AP Breda (NL). **DOOREN VAN, Theodorus, Johannes, Godfried, Maria** [NL/NL]; Henri Tijssenstraat 56, NL-6042 BZ Roermond (NL). **BOESTEN, Wilhelmus, Hubertus, Joseph** [NL/NL]; Brountslaan 9, NL-6132 BJ Sittard (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROCESS FOR THE PREPARATION OF A B-LACTAM ANTIBIOTIC


(57) Abstract: The invention relates to mutated penicillin acylases having a high synthesis/hydrolysis ratio in comparison with wild-type penicillin acylases and at least 1% of the activity. The invention also relates to a process for the enzymatic preparation of a β -lactam antibiotic from a β -lactam nucleus and an activated side chain with the aid of mutated penicillin acylases.

WO 03/055998 A2

PROCESS FOR THE PREPARATION OF A β -LACTAM ANTIBIOTIC

The invention relates to a mutated penicillin acylase and a process for the preparation of a β -lactam antibiotic wherein a β -lactam nucleus is acylated with the aid of an activated side chain in the presence of a mutated penicillin acylase.

5 Penicillin acylases are a group of hydrolases originating from microorganisms, for example bacteria, that are capable of reversibly hydrolyzing the 6-acyl group of penicillins or the 7-acyl group of cephalosporins to form the corresponding free amines without the ring structure of the penicillins or cephalosporins being destroyed. Reaction diagram I illustrates a hydrolysis reaction. A few examples of side chains R in the
 10 penicillin compound are phenylacetyl and phenoxyacetyl.




Reaction diagram I


15 Penicillin acylases are variously known as for example penicillin amidase or benzyl penicillin hydrolase (enzyme classification E.C. 3.5.1.11).

The term β -lactam antibiotic comprises all antibiotics that contain a condensed ring system as shown by formula II or III, where X=S or O. The best-known β -lactam antibiotics are the penicillins and cephalosporins.

In the context of the present application penicillins are defined as compounds according to formula (II) and cephalosporins as compounds according to formula (III),



(II)



(III)

5

where

X = S, O, C, S(O), or SO₂,

R₁ = side chain, such as for example phenylacetyl, phenoxyacetyl, hydroxyphenylglycyl, phenylglycyl, dihydrophenylglycyl and derivatives thereof and acetyl, adipyl, glutaryl and derivatives thereof,

10

R₂, R₃ = Cl, aliphatic or aromatic groups, optionally with one or more O, S or N atoms,

R₄ = OH, aliphatic or aromatic alcohols and derivatives thereof, optionally with one or more O, S or N atoms.

Side chains in the context of the present invention may include any suitable compounds that can be attached to the 6-penam or 7-cephem position of a β -lactam nucleus, resulting in an antibiotically active compound.


15

The aliphatic group in R₂ or R₃ preferably contains 1-4 C atoms, and is preferably a methyl group.


Penicillins or cephalosporins are prepared for example by acylating the 6-amino-group of 6-aminopenicillanic acid (6-APA) or a derivative thereof as shown in formula (IV), or the 7-amino group of 7-aminodesacetoxycephalosporanic acid (7-ADCA) or a derivative thereof as shown in formula (V), with the aid of an activated side chain and a penicillin acylase enzyme. Also 7-aminocephalosporanic acid (7-ACA)-nuclei can be acylated with the aid of penicillin acylases. Derivatives of the compounds according to

20

formula (IV) or (V) are understood to be compounds according to formula (IV) or (V), respectively, wherein X, R₂, R₃, and R₄ have the meaning shown in formula (II) and (III), respectively.



(IV)



(V)

5

where

X = S

10 R₂ = CH₃

R₃ = CH₃

R₄ = OH

Penicillin acylases can be classified both on the basis of their molecular
 15 structure and on the basis of their substrate specificity. There are type I, II and III
 acylases. Type II acylases consist of a heterodimer of a (small) α -subunit and a (large)
 β -subunit. Type IIa, the so-called penicillin G acylases, are active on substrates with a
 hydrophobic side chain such as for example phenylacetyl, the side chain of Penicillin G.
 Short alkyl chains, for example, are recognised also by Type IIa acylases. However,
 20 Type IIa acylases are not active with substrates with charged side chains. For
 substrates with charged side chains Type IIb acylases are suitable. All Type II acylases
 belong to one family. It is known that Type II acylases show high homology in amino acid
 sequence.

In the framework of this application penicillin acylase is understood to be a Type II acylase. In a preferred embodiment the invention relates to Type IIa penicillin acylases.

A mutated penicillin acylase or a penicillin acylase mutant is understood to be a penicillin acylase in which in at least one position an amino acid from the amino acid
5 sequence of a wild type penicillin acylase has been replaced by another amino acid.

Mutants are described by the number of the position of the amino acid which is replaced in the amino acid sequence of the wild type. Before the number it is indicated which amino acid occurs at that place in the wild-type, and after the number it is indicated which amino acid has taken its place in the mutant.

10 SEQ ID No:1 shows the amino acid sequence of an *E.coli* penicillin acylase, including secretion signal. SEQ ID No:2 shows the amino acid sequence of the α -subunit of an *E.coli* penicillin acylase. SEQ ID No:3 shows the amino acid sequence of the β -subunit of an *E.coli* penicillin acylase. In SEQ ID No:4 the amino acid sequence is given of the mutated α -subunit at position 145 of an *E.coli* penicillin acylase (α -R145L).

15 Numerous publications are known in which reference is made to mutated penicillin acylases. In WO98/20120 reference is made for example to the following publications: Prieto et al, Appl. Microbiol.Biotechnol.33 (1990) 553-559, in which it is described that replacement of L-methionine in position 168 in penicillin acylase of
20 *K.citrophila* by L-alanine (M168A), L-valine (M168V), L-asparagine (M168N) or L-tyrosine (M168Y) had an influence on the kinetic parameters for deacylation of penicillin G and penicillin V, while the substitution of Asn375 or Tyr481 by lysine (N375K) and histidine (Y481H), respectively, had no effect. In J. Martin and I. Prieto, Biochimica et Biophysica Acta 1037 (1990) 133-139, a mutant is described in which Met168 is replaced by alanine (M168A). This resulted in improved thermal stability. Replacement of Ser177 in *E.coli*
25 penicillin acylase by glycine (S177G), threonine (S177T), leucine (S177L), or arginine (S177R) produced inactive enzymes (Wang Min et al., Shiyang Shengwu Xuebao 24 (1991) 1, 51, while from Kyeong Sook et al., Journal of Bacteriology 174 (1992) 6270 and Slade et al., Eur. J. Biochem.197, (1991) 75 it is known that Ser290 is an essential amino acid in penicillin acylase of *E.coli*. Replacement of Gly359 by L-aspartic acid
30 (G359D) resulted in a mutated enzyme which was not able to hydrolyze penicillin G but which was able to hydrolyze phthalyl-leucine and phthalyl-glycyl-L-proline. Replacement of Trp431 in Arg (W431R; Gabriel Del Rio et al., Biotechnology and Bioengineering 48

(1995) 141-148) resulted in a mutated penicillin G acylase of *E.coli* with increased stability in a basic environment.

A recent publication is W.B. L. Alkema *et al.*, Protein Engineering, 13, (2000) 857-863, in which the binding site of *E.coli* penicillin acylase is characterised, and in which it is further described that a mutant with L-tyrosine on α 146 (F146Y) was not active for the synthesis of penicillin G from phenylacetamide and 6-aminopenicillanic acid, while mutants with leucine (F146L) or alanine (F146A) at that position were more effective for the synthesis of penicillin G than the wild type.

Patents in which many mutants of penicillin acylases are described are European patent application EP-A-0453048 and international patent application WO 96/05318.

For an economically attractive process for the enzymatic preparation of a β -lactam antibiotic it is desirable that the Synthesis/Hydrolysis ratio (S/H ratio) is high. Preferably the S/H ratio is high and at the same time the enzymatic activity is also sufficiently high.

The Synthesis/Hydrolysis ratio (S/H ratio) is understood to be the molar ratio of synthesis product to hydrolysis product at defined conditions during the enzymatic acylation reaction. Synthesis product is understood to be the β -lactam antibiotic formed from the activated side chain and β -lactam nucleus. Hydrolysis product is understood to be the corresponding acid of the activated side chain.

In the context of the invention enzymatic activity is defined as the volumetric productivity per quantity of dissolved or immobilised enzyme at defined conditions during the enzymatic acylation reaction. Preferably enzymes are applied in immobilised form and the enzymatic activity is defined per quantity of immobilised enzyme.

The volumetric productivity in an acylation reaction can be expressed as the molar quantity of β -lactam antibiotic formed in the acylation reaction at defined conditions during the reaction per unit volume and per unit time.

The S/H ratio is a function of, amongst other things, the concentration of the reactants, the temperature, the pH and the enzyme. It is therefore important to indicate in what conditions an S/H ratio is determined.

A process for the enzymatic preparation of a β -lactam antibiotic from a β -lactam nucleus and an activated side chain with the aid of a penicillin acylase mutant is known from the international patent application WO 98/20120. This publication discloses that a β -lactam antibiotic can be prepared by carrying out an enzymatic acylation

reaction in which a β -lactam nucleus and an activated side chain are contacted with each other in the presence of a penicillin G acylase. The β -lactam antibiotic is formed by coupling the side chain to the nucleus. Activated side chains usually are amides or esters of the side chain.

5 International patent application WO 98/20120 discloses that the enzymatic activity and selectivity for the acylation reaction can be changed by mutating the penicillin G acylase enzyme at one or more amino acid positions. Specifically, good penicillin G acylases result from mutations at the amino acid positions 142 and 146 on the α -subunit and at amino acid positions 24, 56 or 177 on the β -subunit. Particularly, the mutation in
10 position β 24, whereby the L-phenylalanine originally present in the 24 position is replaced by L-alanine (F24A), appears to produce a significantly higher yield in the synthesis of penicillins and cephalosporins with the aid of an activated side chain in the form of an ester.

We found that if an amide is used in combination with the F24A mutant the S/H
15 ratio is relatively high, but the enzymatic activity is so low that the use of this mutant is economically less attractive.

We found it is attractive to use amides as activated side chains, because amides are chemically more stable than esters. A greater chemical stability is understood to mean that hydrolysis of the activated side chain to form the corresponding acid and/or
20 the chemical racemisation of the side chain are significantly lower for amides than for esters. Phenylglycine amide, for example, is around one thousand times more stable than phenylglycine methyl ester at equal temperature and pH.

The object of the invention is therefore to provide a mutated penicillin acylase which, when used in a process for the enzymatic preparation of a β -lactam antibiotic
25 from a β -lactam nucleus and an amide as activated side chain, results in a relatively high S/H ratio and relatively high activity.

Surprisingly, it has been found that a higher S/H ratio is obtained in a process for the preparation of a β -lactam antibiotic whereby, in the presence of a penicillin acylase and with the aid of an activated side chain a β -lactam nucleus is acylated as a
30 mutated penicillin acylase, which acylase has at least one amino acid substitution in a position corresponding to position 145 on the α -subunit of a penicillin acylase originating from *E.coli*. In particular, a higher S/H ratio is obtained in said process in the presence of

a mutated penicillin acylase in which L-Arganine has been replaced in said 145 position by L-Leucine (R145L), L-Lysine (R145K) or L-Cysteine (R145C).

It is known that positions in a penicillin acylase which correspond to a particular position in a penicillin acylase of another wild type can be found by, for example, aligning the amino acid sequences. International patent application WO96/05318, for example, describes how amino acid sequences of penicillin acylases are aligned and shows amino acid sequences for penicillin acylases originating from *E.coli*, *Alcaligenes faecalis*, *Kluyvera citrophila*, *Arthrobacter viscosus* and *P.rettgeri*. It is indicated which amino acid positions in for example *E.coli* correspond with amino acid positions in *A. faecalis* (see Figure 2 of WO96/05318).

The R145L, R145K and R145C mutants, when used in a process for the enzymatic preparation of a β -lactam antibiotic from a β -lactam nucleus and an amide as activated side chain, result in an initial S/H ratio at least twice as high as the initial S/H ratio which is found when a wild-type *E.coli* penicillin G acylase is used, and has an enzymatic activity amounting to more than 1% of the activity of the wild-type *E.coli* penicillin G acylase. The invention also relates to a mutated penicillin acylase which, when used in a process for the enzymatic preparation of a β -lactam antibiotic from a β -lactam nucleus and an amide as activated side chain with the aid of the mutated penicillin acylase, results in an initial S/H ratio at least twice as high as the initial S/H ratio which is found when a wild-type *E.coli* penicillin G acylase is used under the same reaction conditions and which has an enzymatic activity amounting to at least 1% of the activity of the wild-type *E.coli* penicillin G acylase under the same reaction conditions. Preferably, the mutated penicillin acylase according to the invention is an *E.coli* penicillin acylase.

The invention in addition relates to a process for the enzymatic preparation of a β -lactam antibiotic from a β -lactam nucleus and an activated side chain with the aid of a mutated penicillin acylase according to the invention.

In a preferred embodiment the invention relates to a process for the preparation of a β -lactam antibiotic whereby, in the presence of a penicillin acylase according to the invention, a β -lactam nucleus is acylated with the aid of an activated side chain in the form of an amide.

In a preferred embodiment the mutated penicillin acylase is an acylase which, when used in a process for the enzymatic preparation of a β -lactam antibiotic from a β -

lactam nucleus and an amide as activated side chain with the aid of the mutated acylase, results in an at least 3 and preferably 4 times higher initial S/H ratio than the initial S/H ratio which is found when a wild-type *E.coli* penicillin G acylase is used.

5 The enzymatic activity is preferably at least 2%, more preferably at least 5% relative to the activity of the wild-type *E.coli* penicillin G acylase.

International patent application WO96/05318 refers to penicillin acylase mutants α M143V, β L56G and β L177S in connection with an improved S/H ratio for the synthesis of Ampicillin from D-phenylglycine amide and 6-aminopenicillanic acid. However, the S/H ratios cited are not a factor of 2 higher than those for a wild-type *E.coli* penicillin acylase
10 but are significantly lower.

The conversion to be achieved in an acylation reaction can be expressed as the molar quantity of β -lactam antibiotic formed in the acylation reaction at a particular moment during the reaction per molar quantity of reactant used, where the reactant may be either the β -lactam nucleus or the (activated) side chain. In the context of the
15 invention conversion is defined as the quantity of β -lactam antibiotic formed in the acylation reaction (in moles) per quantity of β -lactam nucleus used (in moles).

During an enzymatic acylation reaction the S/H ratio generally decreases. The conversion generally first increases and later decreases. The S/H ratio is a function of the conversion, amongst other things. The S/H ratios of different penicillin acylases are
20 preferably compared at equal conversion. They are most usually compared at 0% conversion, the so-called initial S/H ratio, which thus is a measure of the S/H ratio. The initial S/H ratio is understood to be the S/H ratio at 0% conversion, hence at time $t = 0$. The initial S/H ratio can be determined with sufficient accuracy by carrying out the acylation reaction until a sufficiently high conversion is reached, at least 30%, preferably
25 at least 50%, and then constructing a graph of the S/H ratio versus conversion and extrapolating it to 0 % conversion. It is desirable to determine the initial S/H ratio through extrapolation, since this improves the accuracy of the determination of the initial S/H ratio. For accurate determination it is desirable to have sufficient data points, for instance, at least three data points, which should preferably represent a difference in
30 conversion of at least 5% and wherein preferably none of the measuring points are located where the conversion is less than 10%.

During an enzymatic acylation reaction the volumetric productivity and the enzymatic productivity generally decrease over time. The volumetric productivity and the

enzymatic activity are a function of the conversion. The enzymatic activities of different penicillin acylases are preferably compared at equal conversion. They are most usually compared at 0% conversion, the so-called initial enzymatic activity, which thus is a measure of enzymatic activity. The initial enzymatic activity is understood to be the enzymatic activity at 0% conversion, hence at time $t = 0$. The initial enzymatic activity can be determined with sufficient accuracy by carrying out the acylation reaction until a certain high conversion is reached, preferably at least 30%, more preferably at least 50%, and then constructing a graph of the enzymatic activity versus the conversion and extrapolating it to 0% conversion. It is desirable to determine the initial enzymatic activity through extrapolation, since this improves the accuracy of the determination of the initial enzymatic activity. For accurate determination it is also desirable to have sufficient data points, preferably, at least three data points, which data points preferably represent a difference in conversion of at least 2% and wherein preferably none of the measuring points should be located where the conversion is less than 1%.

Suitable reaction conditions for the performance of an enzymatic acylation reaction in which a mutated or unmutated penicillin acylase is used are known to one skilled in the art.

The molar ratio of activated side chain to β -lactam nucleus, i.e. the total quantity of activated side chain added divided by the total quantity of β -lactam nucleus added, both expressed in moles, may vary between wide limits. Preferably the molar ratio is between 0.5 and 2.0, in particular between 0.7 and 1.8.

The temperature at which the enzymatic acylation reaction is carried out is generally lower than 40 °C, preferably between -5 and 35 °C. The pH at which the enzymatic acylation reaction is carried out generally lies between 5.5 and 9.5, preferably between 6.0 and 9.0.

Preferably the reaction is almost completely terminated when the maximum conversion is all but reached. A suitable embodiment to terminate the reaction is lowering the pH, preferably to a value between 4.0 and 6.3, in particular between 4.5 and 5.7. Another suitable embodiment is lowering the temperature of the reaction mixture as soon as maximum conversion is achieved. A combination of both embodiments is also possible.

In the context of the invention, a decrease in pH can be accomplished for example by the addition of an acid. Suitable acids are for example mineral acids, in

particular sulphuric acid, hydrochloric acid solution or nitric acid and carboxylic acids, for example acetic acid, oxalic acid and citric acid. An increase in pH can be accomplished for example by the addition of a base. Suitable bases are for example inorganic bases, in particular ammonia, potassium hydroxide or sodium hydroxide solution and organic
5 bases, for example triethylamine and D-phenylglycine amide. Preferably ammonia is applied.

The enzymatic acylation reaction can be carried out in water. If desired, the reaction mixture may also contain an organic solvent or a mixture of organic solvents, preferably less than 30 vol.%. Examples of organic solvents that may be applied are
10 alcohols with 1-7 C-atoms, for example a monoalcohol, in particular methanol or ethanol; a diol, in particular ethylene glycol or a triol, in particular glycerol.

The enzymatic acylation reaction is preferably carried out as a batch process. If desired, it is also possible to carry out the reaction continuously. Suitable examples of β -lactam nuclei that can be used in the process according to the invention are penicillin
15 derivatives, for example 6-APA, and cephalosporin derivatives, for example a 7-aminocephalosporanic acid with or without a substituent on the 3-site, for example 7-ACA, 7-ADCA, 7-aminodeacetylcephalosporanic acid (7-ADAC), 7-amino-3-chloro-ceph-3-em-4-carboxylic acid (7-ACCA) and 7-amino-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

20 Side chains in the context of the present invention may include any suitable compounds that can be attached to the 6-penam or 7-cephem position of a β -lactam nucleus, resulting in an antibiotically active compound. Phenylglycine, p-hydroxyphenylglycine and dihydrophenylglycine are examples of suitable side chains. As an activated side chain in the (enzymatic) acylation reaction use may be made of for
25 example an amide (primary, secondary, tertiary) or an ester of said side chains, for instance an amide or ester of phenylglycine, p-hydroxyphenylglycine or dihydrophenylglycine, preferably an amide or a lower alkyl (1-4C) ester, for example a methyl ester. The activated side chain may also include salts of the esters or amides. Preferably, phenylglycine amide is used as an activated side chain.

30 β -lactam antibiotics that are preferably prepared by the process according to the invention are amoxicillin, ampicillin, cephalixin, cefadroxil, cephadrine and cefaclor.

Mutants of penicillin acylases can be made by starting from any known penicillin acylase. Microorganisms from which penicillin acylase enzymes can be obtained are for

example *Acetobacter*, in particular *Acetobacter pasteurianum*, *Aeromonas*, *Alcaligenes*, in particular *Alcaligenes faecalis*, *Aphanocladium*, *Bacillus* sp., in particular *Bacillus megaterium*, *Cephalosporium*, *Escherichia*, in particular *Escherichia coli*, *Flavobacterium*, *Fusarium*, in particular *Fusarium oxysporum* and *Fusarium solani*,
5 *Kluyvera*, *Mycoplana*, *Protaminobacter*, *Proteus*, in particular *Proteus rettgeri*, *Pseudomonas* and *Xanthomonas*, in particular *Xanthomonas citrii*.

Mutated penicillin acylases can be prepared in any known manner. A suitable process is for example a process in which a polymerase chain reaction (PCR) is used to introduce a mutation in the DNA that codes for a penicillin acylase. In the PCR process a
10 mutation is introduced, with the aid of a synthetic oligonucleotide, in the desired site in a DNA sequence that codes for a penicillin acylase. Use may be made of for example the oligonucleotide

5'-TGCCAGATTATCGATTTCGCTAGTACTATCAGAGAACAAGTTTGCCAT-3'

in which the underlined codon codes for L-leucine, for the purpose of introducing a
15 mutation in position 145 of the α -subunit of an *E.coli* penicillin acylase with the codon for L-Arginine being replaced in that position by a codon for L-Leucine. Oligonucleotides as described above, in which the underlined codon is replaced by ACA or CTT can be used in order to introduce in the same position a codon for L-Cysteine or L-Lysine, respectively.

20 After the introduction of the mutation in the DNA sequence, the obtained DNA sequence may be cloned into a vector. The vector may subsequently be used for transforming a host cell. The host cell is then cultivated under conditions suitable for expression of the mutated penicillin acylase.

The invention also relates to a nucleic acid sequence that codes for the mutated
25 penicillin acylase according to the invention and to an expression vector containing the nucleic acid sequence according to the invention with a functionally linked promoter that is suitable for expression of the nucleic acid sequence in a host cell. The invention also relates to a host cell containing the expression vector and to a process for the preparation of a mutated penicillin acylase according to the invention in which the host
30 cell is cultivated under conditions suitable for production of the mutated penicillin acylase. *E.coli* is preferably used as the host cell.

Preferably a penicillin acylase is applied in immobilised form, since the immobilised enzyme can then be readily separated and recycled.

The invention will be elucidated on the basis of the examples without being limited thereby.

Nomenclature of amino acids

5	Amino acid	3-letter abbreviation	1-letter abbreviation
	L-alanine	Ala	A
	L-cysteine	Cys	C
	L-asparaginic acid	Asp	D
	L-glutaminic acid Glu	E	
10	L-phenylalanine	Phe	F
	L-glycine	Gly	G
	L-histidine	His	H
	L-isoleucine	Ile	I
	L-lysine	Lys	K
15	L-leucine	Leu	L
	L-methionine	Met	M
	L-asparagine	Asn	N
	L-proline	Pro	P
	L-glutamine	Gl	Q
20	L-arginine	Arg	R
	L-serine	Ser	S
	L-threonine	Thr	T
	L-tyrosine	Tyr	Y
	L-valine	Val	V
25	L-tryptophan	Trp	W

List of abbreviations

7-ADCA : 7-aminodesacetoxycephalosporanic acid

6-APA : 6-aminopenicillanic acid

	AMPI	: ampicillin
	CEX	: cephalexin
	PG	: D-phenylglycine
	PGA	: D-phenylglycine amide
5	PGM.HCL	: D-phenylglycine methyl ester HCl salt
	HPGM	: D-p-hydroxyphenylglycine methyl ester

Examples and comparative experiments

Penicillin acylase (wild type)

10 Assemblase™ is an immobilised *E. coli* penicillin acylase of *E. coli* ATCC 1105 as described in WO-A-99/20786 and in WO-A-97/04086. The acylase was immobilised on spherules as described in EP-A-222462, utilising gelatin and chitosan as gelating compounds and glutaraldehyde as a crosslinker.

15 The activity of the *E. coli* penicillin acylase produced is determined by the quantity of enzyme that is added to the activated spherules and amounted to 3 ASU/g dry weight. 1 ASU (Amoxicillin Synthesis Unit) is defined as the quantity of enzyme needed to produce 1 g of Amoxicillin.3H₂O per hour from 6-APA and HPGM (at 20 °C; 6.5 mass% 6-APA and 6.5 mass% HPGM).

20 Example 1

Mutated penicillin acylase (R145L)

Preparation of mutants

25 In a polymerase chain reaction (PCR) a DNA fragment was amplified by thermocycling. For this purpose use was made of 2 primers each of which was complementary to the DNA (*E.coli*) of one of the two ends of the fragment (template) which was amplified. After the primers had been bound to the template the DNA polymerase was able to bind to the primer template complex and the DNA was amplified. During thermocycling the following processes took place:
Step 1: Incubation at 94 °C: the double strand template melts and single strand template
30 DNA is formed.

Step 2: Incubation at 55 °C: The primers adhere to the complementary DNA of the template.

Step 3: Incubation at 72 °C: The polymerase binds to the primer template complex and amplifies the DNA.

5 By repeating these 3 steps a number of times the fragment was amplified on the template DNA which was flanked by the sequences that are complementary to the primer sequence.

The α R145L mutation was made by the PCR described above. A fragment of 305 base pairs was amplified with the aid of the following reaction mixture:

10 1 μ l primer R145Lfw (100 ng/ μ l): 5'-GAAGTGCTTGGCAAA-3'

1 μ l primer R145Lrv (100ng/ μ l):

5'-TGCCAGATTATCGATTTTCGCTAGTACTATCAGAGAACAAGTTTGCCAT-3'

(in which the underlined codon codes for L-leucine)

1 μ l plasmid DNA, pEC (~ 20 ng/ μ l stock solution)

15 2 μ l dNTPs (10 mM stock solution)

10 μ l 10 X *Pwo* buffer

1 μ l *Pwo* polymerase

84 μ l H₂O

20 The following temperature programme was used to heat the reaction mixture:

1 cycle of 1 min. at 94 °C, 25 cycles of: 1 min at 94 °C followed by 1 min. at 55 °C

followed by 1 min. at 72°C, 1 cycle of 5 min. at 72 °C

The PCR product and the plasmid pEC were subsequently cut with the restriction enzymes *Cla*I and *Eco*RV. Both products were then applied on an agarose gel and purified with the aid of the Quiaex kit from Quiagen. After purification both fragments were ligated. This was done using the following reaction mix.

25 10 μ l PCR product cut with *Eco*RV and *Cla*I in H₂O (300 ng DNA in total)

1 μ l plasmid DNA cut with *Eco*RV and *Cla*I in H₂O (100 ng DNA in total)

2 μ l ligation buffer

30 1 μ l ligase

6 μ l H₂O

The reaction was carried out at room temperature for 16 hours.

Subsequently 10 µl of this reaction mix was used to transform CaCl₂ competent *E.coli* HB101. Transformation took place through standard methods described in Sambrook et al, 'Molecular Cloning: a Laboratory Manual', Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989. All enzymes and buffers used were from Boehringer Mannheim.

5 By sequencing it was verified that the mutant obtained contained the desired nucleotide sequence.

Purification protocol

10 The recombinant enzyme was obtained as follows. *E. coli* with the plasmid pEC containing the gene for penicillin acylase with the relevant mutation was cultivated at 17 °C, 150 rpm, in LB medium with 0.1mM IPTG. The cells were harvested at an optical density at 600 nm (OD₆₀₀) of 2 by centrifuging at 5000 x g for 10 minutes. The pellet was then resuspended in ice-cold buffer A (20% sucrose, 100 mM Tris-HCl, pH 8.0, 10 mm EDTA), in 1/10th of the original volume. Next the cells were centrifuged again for 10 minutes at 5000 x g. The pellet was then resuspended in ice-cold buffer B (1mM EDTA) and centrifuged at 5000 x g for 10 minutes. The supernatant is the periplasmatic extract, to which phosphate buffer pH 7.0 was added to a final concentration of 50 mM.

20 (NH₄)₂SO₄ was added stepwise to the supernatant to a final concentration of 1.5 M after which the extract was centrifuged at 10,000 x-g for 20 minutes. The supernatant was then placed on a Resource Phe (Amersham-Pharmacia Biotech) and eluted with a linear gradient of 1.5 M – 0 M (NH₄)₂SO₄. The final concentration of the purified enzyme was determined by measuring the absorption at 280 nm (A₂₈₀) (cell length 1 cm) and by using an extinction coefficient of 210.000 M⁻¹·cm⁻¹.

25 The plasmid pEC is shown in Figure 1.

Immobilised Pen-G acylase mutant R145L

30 The mutated penicillin acylase (α145L) was immobilised in the same way as described for Assemblase™, except that the mutant R145L was used instead of the wild-type *E.coli* Pen-G acylase and the enzyme loading was chosen to be a factor of 0.87

(normal loading) and 1.35 (higher loading) higher, respectively, based on immobilised protein.

Reference experiment A

Immobilised Pen-G acylase mutant β F24A

The mutated penicillin acylase (β F24A) was immobilised in the same way as described for Assemblase™, except that the mutant β F24A was used instead of the wild-type *E.coli* Pen-G acylase. The enzyme loading was chosen to be same, based on immobilised protein.

Synthesis of cephalexin with Assemblase™ (immobilised wild-type Pen-G acylase) and PGA

An enzyme reactor (100 ml), with a sieve bottom with 175 μ m gauze, was filled with 20 g nett-wet Assemblase™. A preparation reactor (100 ml) was filled with 40.0 ml water ($T = 2^\circ\text{C}$), 0.10 g sodium bisulphite, 10.8 g 7-ADCA (49.6 mmol) and 7.1 g PGA (46.8 mmol). 0.45 g concentrated ammonia was added, after which the suspension was stirred for 15 minutes at $T = 2^\circ\text{C}$. The pH was 7.8. Subsequently the suspension was transferred into the enzyme reactor at $t = 0$ with the aid of 10.0 ml water ($T = 2^\circ\text{C}$). At $t = 0$ the stirrer in the enzyme reactor was started. The temperature was kept at $T = 2^\circ\text{C}$. After about 90 minutes all 7-ADCA had dissolved; next, a clear solution, apart from solid Assemblase™, was present.

After 166 minutes the pH had risen to 8.80, $[\text{PG}] = 1.10$ mass%, the conversion = 70 % w.r.t. the initial 7-ADCA amount and the S/H = 6.6. The initial enzymatic activity is calculated to be $\sim 8.2 \mu\text{mol CEX} / (\text{min} \cdot \text{mg enzyme})$. The S/H as a function of conversion is shown in Figure 2.

Reference experiment B

Synthesis of cephalexin with immobilised Pen-G acylase mutant β F24A and PGA

A similar enzyme reactor as in reference experiment A was filled with 25.0 g nett-wet of immobilised Pen-G acylase mutant β F24A. A preparation reactor was filled

with 40 ml water (2°C), 0.10 sodium bisulphite, 10.0 g 7-ADCA (45.9 mmol) and 7.2 g PGA (47.5 mmol). 0.45 g ammonia was added. Conditions were further as described in reference experiment A.

After 280 minutes the pH had risen to 7.9, [PG] = 0.05 mass%, the conversion =
5 23 % w.r.t. the initial 7-ADCA amount and the S/H = 33. The initial enzymatic activity is calculated to be ~0.13 $\mu\text{mol CEX} / (\text{min} \cdot \text{mg enzyme})$. The S/H as a function of conversion is shown in Figure 2.

Example 2

10 Synthesis of cephalixin with immobilised Pen-G acylase mutant R145L (normal loading) and PGA

A similar enzyme reactor as in reference experiment A was filled with 20.0 g nett-wet immobilised Pen-G acylase mutant (R145L, normal loading). A preparation reactor was filled with 47.0 ml water (2°C), 0.16 g sodium bisulphite, 15.5 g 7-ADCA
15 (70.9 mmol) and 11.5 g PGA (76.0 mmol). Conditions were further as described in reference experiment A.

After 315 minutes the pH had risen to 8.58, [PG] = 0.66 mass%, conversion =
81 % w.r.t. the initial 7-ADCA amount and the S/H = 13.8. The initial enzymatic activity is
calculated to be ~0.71 $\mu\text{mol CEX} / (\text{min} \cdot \text{mg enzyme})$. The S/H as a function of
20 conversion is shown in Figure 2.

The results (Figure 2) show that a higher S/H ratio (13.8) in combination with a high conversion (83%) in Cephalixin synthesis is obtained with Pen-G acylase mutant R145L (Example 1), compared to the wild type Pen G acylase (Reference experiment A). With
25 Pen-G acylase mutant βF24A (Reference experiment B) only a low conversion (23%) is obtained. In addition, the initial enzymatic activity of Pen-G acylase mutant R145L is 8.8% of wild type Pen G acylase, whereas the initial enzymatic activity of Pen-G acylase mutant βF24A is only 1.6% of wild type Pen G acylase.

30 Reference experiment C

Synthesis of ampicillin with Assemblase™ (immobilised wild-type Pen-G acylase) and PGA

An enzyme reactor (750 ml), with a sieve bottom with 175 µm gauze was filled with 150 g nett-wet Assemblase™.

5 A preparation reactor (600 ml) was filled with 250 ml water ($T = 10\text{ }^{\circ}\text{C}$) and 71.6 g PGA (475 mmol). At $T = 10\text{ }^{\circ}\text{C}$, 65.8 g 6-APA (300 mmol) was added in small portions in 15 minutes with cooling and with the pH being kept at 7.0 by titration with 6N H_2SO_4 . The mixture was stirred for 15 minutes at $T = 10\text{ }^{\circ}\text{C}$ and subsequently transferred into the enzyme reactor at $t = 0$ with the aid of 50.0 ml water ($T = 10\text{ }^{\circ}\text{C}$). At $t = 0$ the stirrer in
10 the enzyme reactor was started. The pH was kept at 7.0 by titration with 6N H_2SO_4 . The temperature was kept at $10\text{ }^{\circ}\text{C}$.

At $t = 160$ minutes the quantity of ampicillin was maximum and the pH was lowered to 5.6 by addition of 6N H_2SO_4 . At $t = 160$ minutes the conversion = 91-92 % w.r.t. the initial 6-APA amount and the S/H = 1.67. The initial enzymatic activity is
15 calculated to be $\sim 1.4\text{ }\mu\text{mol AMPI} / (\text{min} \cdot \text{mg enzyme})$. The S/H as a function of conversion is shown in Figure 3.

Reference experiment D

Synthesis of ampicillin with immobilised Pen-G acylase mutant βF24A and PGA

20 A similar enzyme reactor as in reference experiment C was filled with 95.5 g nett-wet immobilised Pen-G acylase mutant βF24A . A preparation reactor (600 ml) was filled with 200 ml water ($T = 10\text{ }^{\circ}\text{C}$), 30.0 g 6-APA (139.0 mmol) and 22.8 g PGA (140 mmol). The pH was 6.7. The mixture was stirred for 15 minutes at $T = 10\text{ }^{\circ}\text{C}$ and subsequently transferred into the enzyme reactor at $t = 0$ with the aid of 50.0 ml water (T
25 $= 10\text{ }^{\circ}\text{C}$). At $t = 0$ the stirrer in the enzyme reactor was started. The pH was kept at 6.7 by titration with 6N H_2SO_4 . The temperature was kept at $10\text{ }^{\circ}\text{C}$.

At $t = 300$ minutes the conversion was only 11.1 % and the S/H ratio was 19.1. The initial enzymatic activity is calculated to be $\sim 0.057\text{ }\mu\text{mol AMPI} / (\text{min} \cdot \text{mg enzyme})$. The S/H as a function of conversion is shown in Figure 3.

Example 3

Synthesis of ampicillin with immobilised Pen-G acylase mutant R145L and PGA

A similar enzyme reactor as in reference experiment C was filled with 90 g net-
wet immobilised Pen-G acylase mutant R145L (normal loading. Then 59.8 g PGA, 65.8 g
6-APA (300 mmol) and 225 ml water ($T = 10\text{ }^{\circ}\text{C}$) were added and stirred for 15 minutes
at $T = 10\text{ }^{\circ}\text{C}$. Then 59.8 g PGA (397 mmol) was added ($t = 0$). After 10 minutes 1.0 g
ampicillin trihydrate was added. The temperature being kept at $T = 10\text{ }^{\circ}\text{C}$ and the pH
being kept at 6.9 by titration with 50% acetic acid. A total of 43 ml 50% acetic acid was
needed. At $t = 390$ minutes the quantity of ampicillin was maximum and the pH was
lowered to 5.6 by addition of 50% acetic acid.

At $t = 390$ minutes the quantity of ampicillin was maximum and the pH was
lowered to 5.6 by addition of 50% acetic acid (another 10 ml). The conversion of was 87-
88% relative to the quantity of 6-APA used and the S/H ratio was 14.5. The initial
enzymatic activity is calculated to be $\sim 0.94\text{ }\mu\text{mol AMPI} / (\text{min} \cdot \text{mg enzyme})$. The S/H as
a function of conversion is shown in Figure 3.

The results show (Figure 3) that when Pen-G acylase mutant R145L is used in
Ampicillin synthesis a higher S/H ratio (14.5) is obtained at high conversion (Example II)
compared to wild type Pen G acylase (Reference experiment C). With Pen-G acylase
mutant βF24A (Reference experiment D) only a low conversion is obtained. In addition,
the initial enzymatic activity of Pen-G acylase mutant R145L is 67% of the wild-type
PenG acylase, whereas the initial enzymatic activity of Pen-G acylase mutant βF24A is
only 4% of the wild-type PenG acylase.

CLAIMS

1. A mutated penicillin acylase which acylase has at least one amino acid
5 substitution in a position corresponding to position 145 on the α -subunit of the penicillin
acylase originating from *E.coli*
2. A mutated penicillin acylase according to claim 1, in which L-Arginine has been
replaced in said 145 position by L-Leucine, L-Lysine or L-Cysteine.
- 10 3. A mutated penicillin acylase, which, when used in a process for the enzymatic
preparation of a β -lactam antibiotic from a β -lactam nucleus and an amide as an
activated side chain with the aid of the mutated penicillin acylase results in an initial S/H
ratio at least twice as high as the initial S/H ratio which is found when a wild-type *E.coli*
15 penicillin G acylase is used under the same reaction conditions and which has an
enzymatic activity amounting to at least 1% of the activity of the wild-type *E.coli* penicillin
G acylase under the same reaction conditions.
4. A mutated penicillin acylase according to anyone of the claims 1 to 3,
20 characterised in that the penicillin acylase is an *E.coli* penicillin acylase.
5. Process for the preparation of a β -lactam antibiotic wherein a β -lactam nucleus is
acylated with the aid of an activated side chain in the presence of a mutated penicillin
acylase, characterised in that a mutated penicillin acylase enzyme according to anyone
25 of the claims 1 to 3 is used.
6. Process according to claim 5, characterised in that an amide is used as activated
side chain.
- 30 7. Process according to claim 5 or 6, characterised in that the β -lactam antibiotic is
a cephalosporin.

8. Process according to claim 5 or 6, characterised in that the β -lactam antibiotic is a penicillin.

9. A nucleic acid sequence that codes for the mutated penicillin acylase according to anyone of the claims 1 to 3.

5

10. An expression vector containing the nucleic acid sequence as defined in claim 9 with a functionally linked promotor suitable for expression of the nucleic acid sequence in a host cell.

10 11. A host cell containing the expression vector of claim 10.

12. A process for the preparation of a mutated enzyme according to anyone of the claims 1 to 3 in which the host cell is cultivated under conditions suitable for the production of the mutated penicillin acylase.

15

15

Expression plasmid pEC




Figure 1

Start	End	Name	Description
30	270	FdT	transcription terminator (phage Fd)
371	801	f1 ori	origin of replication (phage f1)
975		ori322	origin of replication plasmid pBR322
2565	1906	cat	chloramphenicol acetyl transferase
2815	2905	tac	tac (hybrid trp-lac) promoter
2920	5460	EC_PGA	<i>E.coli</i> penG acylase
3454		Clal	silent mutation introducing Clal restriction site

CEPHALEXIN SYNTHESIS




Figure 2




Figure 3

SEQUENCE LISTING

<110> DSM NV

<120> Werkwijze voor de bereiding van een beta-lactam
antibioticum

<130> 20538WO

<140>

<141>

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 846

<212> PRT

<213> Escherichia coli

<400> 1

Met Lys Asn Arg Asn Arg Met Ile Val Asn Cys Val Thr Ala Ser Leu
1 5 10 15Met Tyr Tyr Trp Ser Leu Pro Ala Leu Ala Glu Gln Ser Ser Ser Glu
20 25 30Ile Lys Ile Val Arg Asp Glu Tyr Gly Met Pro His Ile Tyr Ala Asn
35 40 45Asp Thr Trp His Leu Phe Tyr Gly Tyr Gly Tyr Val Val Ala Gln Asp
50 55 60Arg Leu Phe Gln Met Glu Met Ala Arg Arg Ser Thr Gln Gly Thr Val
65 70 75 80Ala Glu Val Leu Gly Lys Asp Phe Val Lys Phe Asp Lys Asp Ile Arg
85 90 95Arg Asn Tyr Trp Pro Asp Ala Ile Arg Ala Gln Ile Ala Ala Leu Ser
100 105 110Pro Glu Asp Met Ser Ile Leu Gln Gly Tyr Ala Asp Gly Met Asn Ala
115 120 125Trp Ile Asp Lys Val Asn Thr Asn Pro Glu Thr Leu Leu Pro Lys Gln
130 135 140Phe Asn Thr Phe Gly Phe Thr Pro Lys Arg Trp Glu Pro Phe Asp Val
145 150 155 160Ala Met Ile Phe Val Gly Thr Met Ala Asn Arg Phe Ser Asp Ser Thr
165 170 175Ser Glu Ile Asp Asn Leu Ala Leu Leu Thr Ala Leu Lys Asp Lys Tyr
180 185 190

Gly Val Ser Gln Gly Met Ala Val Phe Asn Gln Leu Lys Trp Leu Val
 195 200 205
 Asn Pro Ser Ala Pro Thr Thr Ile Ala Val Gln Glu Ser Asn Tyr Pro
 210 215 220
 Leu Lys Phe Asn Gln Gln Asn Ser Gln Thr Ala Ala Leu Leu Pro Arg
 225 230 235 240
 Tyr Asp Leu Pro Ala Pro Met Leu Asp Arg Pro Ala Lys Gly Ala Asp
 245 250 255
 Gly Ala Leu Leu Ala Leu Thr Ala Gly Lys Asn Arg Glu Thr Ile Ala
 260 265 270
 Ala Gln Phe Ala Gln Gly Gly Ala Asn Gly Leu Ala Gly Tyr Pro Thr
 275 280 285
 Thr Ser Asn Met Trp Val Ile Gly Lys Ser Lys Ala Gln Asp Ala Lys
 290 295 300
 Ala Ile Met Val Asn Gly Pro Gln Phe Gly Trp Tyr Ala Pro Ala Tyr
 305 310 315 320
 Thr Tyr Gly Ile Gly Leu His Gly Ala Gly Tyr Asp Val Thr Gly Asn
 325 330 335
 Thr Pro Phe Ala Tyr Pro Gly Leu Val Phe Gly His Asn Gly Val Ile
 340 345 350
 Ser Trp Gly Ser Thr Ala Gly Phe Gly Asp Asp Val Asp Ile Phe Ala
 355 360 365
 Glu Arg Leu Ser Ala Glu Lys Pro Gly Tyr Tyr Leu His Asn Gly Lys
 370 375 380
 Trp Val Lys Met Leu Ser Arg Glu Glu Thr Ile Thr Val Lys Asn Gly
 385 390 395 400
 Gln Ala Glu Thr Phe Thr Val Trp Arg Thr Val His Gly Asn Ile Leu
 405 410 415
 Gln Thr Asp Gln Thr Thr Gln Thr Ala Tyr Ala Lys Ser Arg Ala Trp
 420 425 430
 Asp Gly Lys Glu Val Ala Ser Leu Leu Ala Trp Thr His Gln Met Lys
 435 440 445
 Ala Lys Asn Trp Gln Glu Trp Thr Gln Gln Ala Ala Lys Gln Ala Leu
 450 455 460
 Thr Ile Asn Trp Tyr Tyr Ala Asp Val Asn Gly Asn Ile Gly Tyr Val
 465 470 475 480
 His Thr Gly Ala Tyr Pro Asp Arg Gln Ser Gly His Asp Pro Arg Leu
 485 490 495

Pro Val Pro Gly Thr Gly Lys Trp Asp Trp Lys Gly Leu Leu Pro Phe
 500 505 510
 Glu Met Asn Pro Lys Val Tyr Asn Pro Gln Ser Gly Tyr Ile Ala Asn
 515 520 525
 Trp Asn Asn Ser Pro Gln Lys Asp Tyr Pro Ala Ser Asp Leu Phe Ala
 530 535 540
 Phe Leu Trp Gly Gly Ala Asp Arg Val Thr Glu Ile Asp Arg Leu Leu
 545 550 555 560
 Glu Gln Lys Pro Arg Leu Thr Ala Asp Gln Ala Trp Asp Val Ile Arg
 565 570 575
 Gln Thr Ser Arg Gln Asp Leu Asn Leu Arg Leu Phe Leu Pro Thr Leu
 580 585 590
 Gln Ala Ala Thr Ser Gly Leu Thr Gln Ser Asp Pro Arg Arg Gln Leu
 595 600 605
 Val Glu Thr Leu Thr Arg Trp Asp Gly Ile Asn Leu Leu Asn Asp Asp
 610 615 620
 Gly Lys Thr Trp Gln Gln Pro Gly Ser Ala Ile Leu Asn Val Trp Leu
 625 630 635 640
 Thr Ser Met Leu Lys Arg Thr Val Val Ala Ala Val Pro Met Pro Phe
 645 650 655
 Asp Lys Trp Tyr Ser Ala Ser Gly Tyr Glu Thr Thr Gln Asp Gly Pro
 660 665 670
 Thr Gly Ser Leu Asn Ile Ser Val Gly Ala Lys Ile Leu Tyr Glu Ala
 675 680 685
 Val Gln Gly Asp Lys Ser Pro Ile Pro Gln Ala Val Asp Leu Phe Ala
 690 695 700
 Gly Lys Pro Gln Gln Glu Val Val Leu Ala Ala Leu Glu Asp Thr Trp
 705 710 715 720
 Glu Thr Leu Ser Lys Arg Tyr Gly Asn Asn Val Ser Asn Trp Lys Thr
 725 730 735
 Pro Ala Met Ala Leu Thr Phe Arg Ala Asn Asn Phe Phe Gly Val Pro
 740 745 750
 Gln Ala Ala Ala Glu Glu Thr Arg His Gln Ala Glu Tyr Gln Asn Arg
 755 760 765
 Gly Thr Glu Asn Asp Met Ile Val Phe Ser Pro Thr Thr Ser Asp Arg
 770 775 780
 Pro Val Leu Ala Trp Asp Val Val Ala Pro Gly Gln Ser Gly Phe Ile
 785 790 795 800

Ala Pro Asp Gly Thr Val Asp Lys His Tyr Glu Asp Gln Leu Lys Met
 805 810 815

Tyr Glu Asn Phe Gly Arg Lys Ser Leu Trp Leu Thr Lys Gln Asp Val
 820 825 830

Glu Ala His Lys Glu Ser Gln Glu Val Leu His Val Gln Arg
 835 840 845

<210> 2

<211> 209

<212> PRT

<213> Escherichia coli

<400> 2

Glu Gln Ser Ser Ser Glu Ile Lys Ile Val Arg Asp Glu Tyr Gly Met
 1 5 10 15

Pro His Ile Tyr Ala Asn Asp Thr Trp His Leu Phe Tyr Gly Tyr Gly
 20 25 30

Tyr Val Val Ala Gln Asp Arg Leu Phe Gln Met Glu Met Ala Arg Arg
 35 40 45

Ser Thr Gln Gly Thr Val Ala Glu Val Leu Gly Lys Asp Phe Val Lys
 50 55 60

Phe Asp Lys Asp Ile Arg Arg Asn Tyr Trp Pro Asp Ala Ile Arg Ala
 65 70 75 80

Gln Ile Ala Ala Leu Ser Pro Glu Asp Met Ser Ile Leu Gln Gly Tyr
 85 90 95

Ala Asp Gly Met Asn Ala Trp Ile Asp Lys Val Asn Thr Asn Pro Glu
 100 105 110

Thr Leu Leu Pro Lys Gln Phe Asn Thr Phe Gly Phe Thr Pro Lys Arg
 115 120 125

Trp Glu Pro Phe Asp Val Ala Met Ile Phe Val Gly Thr Met Ala Asn
 130 135 140

Arg Phe Ser Asp Ser Thr Ser Glu Ile Asp Asn Leu Ala Leu Leu Thr
 145 150 155 160

Ala Leu Lys Asp Lys Tyr Gly Val Ser Gln Gly Met Ala Val Phe Asn
 165 170 175

Gln Leu Lys Trp Leu Val Asn Pro Ser Ala Pro Thr Thr Ile Ala Val
 180 185 190

Gln Glu Ser Asn Tyr Pro Leu Lys Phe Asn Gln Gln Asn Ser Gln Thr
 195 200 205

Ala

<210> 3

<211> 557

<212> PRT

<213> Escherichia coli

<400> 3

Ser Asn Met Trp Val Ile Gly Lys Ser Lys Ala Gln Asp Ala Lys Ala
 1 5 10 15

Ile Met Val Asn Gly Pro Gln Phe Gly Trp Tyr Ala Pro Ala Tyr Thr
 20 25 30

Tyr Gly Ile Gly Leu His Gly Ala Gly Tyr Asp Val Thr Gly Asn Thr
 35 40 45

Pro Phe Ala Tyr Pro Gly Leu Val Phe Gly His Asn Gly Val Ile Ser
 50 55 60

Trp Gly Ser Thr Ala Gly Phe Gly Asp Asp Val Asp Ile Phe Ala Glu
 65 70 75 80

Arg Leu Ser Ala Glu Lys Pro Gly Tyr Tyr Leu His Asn Gly Lys Trp
 85 90 95

Val Lys Met Leu Ser Arg Glu Glu Thr Ile Thr Val Lys Asn Gly Gln
 100 105 110

Ala Glu Thr Phe Thr Val Trp Arg Thr Val His Gly Asn Ile Leu Gln
 115 120 125

Thr Asp Gln Thr Thr Gln Thr Ala Tyr Ala Lys Ser Arg Ala Trp Asp
 130 135 140

Gly Lys Glu Val Ala Ser Leu Leu Ala Trp Thr His Gln Met Lys Ala
 145 150 155 160

Lys Asn Trp Gln Glu Trp Thr Gln Gln Ala Ala Lys Gln Ala Leu Thr
 165 170 175

Ile Asn Trp Tyr Tyr Ala Asp Val Asn Gly Asn Ile Gly Tyr Val His
 180 185 190

Thr Gly Ala Tyr Pro Asp Arg Gln Ser Gly His Asp Pro Arg Leu Pro
 195 200 205

Val Pro Gly Thr Gly Lys Trp Asp Trp Lys Gly Leu Leu Pro Phe Glu
 210 215 220

Met Asn Pro Lys Val Tyr Asn Pro Gln Ser Gly Tyr Ile Ala Asn Trp
 225 230 235 240

Asn Asn Ser Pro Gln Lys Asp Tyr Pro Ala Ser Asp Leu Phe Ala Phe
 245 250 255

Leu Trp Gly Gly Ala Asp Arg Val Thr Glu Ile Asp Arg Leu Leu Glu
 260 265 270

Gln Lys Pro Arg Leu Thr Ala Asp Gln Ala Trp Asp Val Ile Arg Gln
 275 280 285

Thr Ser Arg Gln Asp Leu Asn Leu Arg Leu Phe Leu Pro Thr Leu Gln
 290 295 300

Ala Ala Thr Ser Gly Leu Thr Gln Ser Asp Pro Arg Arg Gln Leu Val
 305 310 315 320

Glu Thr Leu Thr Arg Trp Asp Gly Ile Asn Leu Leu Asn Asp Asp Gly
 325 330 335

Lys Thr Trp Gln Gln Pro Gly Ser Ala Ile Leu Asn Val Trp Leu Thr
 340 345 350

Ser Met Leu Lys Arg Thr Val Val Ala Ala Val Pro Met Pro Phe Asp
 355 360 365

Lys Trp Tyr Ser Ala Ser Gly Tyr Glu Thr Thr Gln Asp Gly Pro Thr
 370 375 380

Gly Ser Leu Asn Ile Ser Val Gly Ala Lys Ile Leu Tyr Glu Ala Val
 385 390 395 400

Gln Gly Asp Lys Ser Pro Ile Pro Gln Ala Val Asp Leu Phe Ala Gly
 405 410 415

Lys Pro Gln Gln Glu Val Val Leu Ala Ala Leu Glu Asp Thr Trp Glu
 420 425 430

Thr Leu Ser Lys Arg Tyr Gly Asn Asn Val Ser Asn Trp Lys Thr Pro
 435 440 445

Ala Met Ala Leu Thr Phe Arg Ala Asn Asn Phe Phe Gly Val Pro Gln
 450 455 460

Ala Ala Ala Glu Glu Thr Arg His Gln Ala Glu Tyr Gln Asn Arg Gly
 465 470 475 480

Thr Glu Asn Asp Met Ile Val Phe Ser Pro Thr Thr Ser Asp Arg Pro
 485 490 495

Val Leu Ala Trp Asp Val Val Ala Pro Gly Gln Ser Gly Phe Ile Ala
 500 505 510

Pro Asp Gly Thr Val Asp Lys His Tyr Glu Asp Gln Leu Lys Met Tyr
 515 520 525

Glu Asn Phe Gly Arg Lys Ser Leu Trp Leu Thr Lys Gln Asp Val Glu
 530 535 540

Ala His Lys Glu Ser Gln Glu Val Leu His Val Gln Arg
 545 550 555

<210> 4
 <211> 209
 <212> PRT
 <213> Escherichia coli

<400> 4

Glu Gln Ser Ser Ser Glu Ile Lys Ile Val Arg Asp Glu Tyr Gly Met
 1 5 10 15

Pro His Ile Tyr Ala Asn Asp Thr Trp His Leu Phe Tyr Gly Tyr Gly
 20 25 30

Tyr Val Val Ala Gln Asp Arg Leu Phe Gln Met Glu Met Ala Arg Arg
 35 40 45

Ser Thr Gln Gly Thr Val Ala Glu Val Leu Gly Lys Asp Phe Val Lys
 50 55 60

Phe Asp Lys Asp Ile Arg Arg Asn Tyr Trp Pro Asp Ala Ile Arg Ala
 65 70 75 80

Gln Ile Ala Ala Leu Ser Pro Glu Asp Met Ser Ile Leu Gln Gly Tyr
 85 90 95

Ala Asp Gly Met Asn Ala Trp Ile Asp Lys Val Asn Thr Asn Pro Glu
 100 105 110

Thr Leu Leu Pro Lys Gln Phe Asn Thr Phe Gly Phe Thr Pro Lys Arg
 115 120 125

Trp Glu Pro Phe Asp Val Ala Met Ile Phe Val Gly Thr Met Ala Asn
 130 135 140

Leu Phe Ser Asp Ser Thr Ser Glu Ile Asp Asn Leu Ala Leu Leu Thr
 145 150 155 160

Ala Leu Lys Asp Lys Tyr Gly Val Ser Gln Gly Met Ala Val Phe Asn
 165 170 175

Gln Leu Lys Trp Leu Val Asn Pro Ser Ala Pro Thr Thr Ile Ala Val
 180 185 190

Gln Glu Ser Asn Tyr Pro Leu Lys Phe Asn Gln Gln Asn Ser Gln Thr
 195 200 205

Ala

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.